Three injured in blast at Alembic India plant; McKinsey says old manufacturing model dead;

> Three workers at an Alembic Pharmaceuticals plant in Vadodara, India, were injured when an explosion and fire gutted the solvent recovery facility. Story

> Australian radiopharmaceutical company Cyclopharm will invest up to $7.5 million Australian ($7.8 million) in a cyclotron manufacturing facility in Brisbane as part of a three-way partnership. Story

> The FDA reports that Samantha Lynn Inc. is voluntarily recalling 500 lots of Reumofan Plus Tablets, used for muscle and arthritis pain, because testing found the supplement contains methocarbamol and diclofenac and using it could lead to anaphylaxis. Release

> GBI Research has a new report detailing the cost advantages it sees for India in the production of biosimilars. Release

> Cook Medical has opened a $19 million, 60,000-square-foot PTFE tubing manufacturing plant in Canton, IL. Release

> The Brazilian regulator Anvisa has extended until next month the deadline for public comment on plans to require excipient manufacturers to be GMP compliant because weeks of job actions by government employees has delayed implementation. Story

And Finally... The McKinsey Quarterly says the pharmaceutical model of developing "blockbuster" drugs "has run its course" and the new market is best served by manufacturing smaller batches with shorter runs to deal with greater complexity and increasing quality expectations. Item

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.